Sosman JA, Kittaneh M, Lolkema MP, Postow MA, Schwartz G, Franklin C, Matano A, Bhansali S, Parasuraman S, Kim K, « A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity », Journal of Clinical Oncology, vol. 32, no 15 Suppl, , p. 9009 (DOI10.1200/jco.2014.32.15_suppl.9009, lire en ligne)
Yen-Shen Lu, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia, Fatima Cardoso, Nadia Harbeck, Sara Hurvitz, Louis Chow, Joohyuk Sohn, Keun Seok Lee, Saul Campos-Gomez, Rafael Villanueva Vazquez, Kyung Hae Jung, K Govind Babu, Paul Wheatley-Price, Michelino De Laurentiis, Young-Hyuck Im, Sherko Kuemmel, Nagi El-Saghir, Ruth O'Regan, Claudia Gasch, Nadia Solovieff, Craig Wang, Yongyu Wang, Arunava Chakravartty, Yan Ji, Debu Tripathy, « Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial », Clinical Cancer research, vol. 28, no 5, (DOI10.1158/1078-0432.CCR-21-3032)
Kurt Samson, « LEE011 CDK Inhibitor Showing Early Promise in Drug-Resistant Cancers », Oncology Times, vol. 36, no 3, , p. 39–40 (DOI10.1097/01.COT.0000444043.33304.c1)
Kim S, Loo A, Chopra R, Caponigro G, Huang A, Vora S, Parasuraman S, Howard S, Keen N, Sellers W, Brain C, « Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6- Reactivating Rb in cancer », Molecular Cancer Therapeutics, vol. 12, no 11, , PR02 (DOI10.1158/1535-7163.TARG-13-PR02)
Sosman JA, Kittaneh M, Lolkema MP, Postow MA, Schwartz G, Franklin C, Matano A, Bhansali S, Parasuraman S, Kim K, « A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity », Journal of Clinical Oncology, vol. 32, no 15 Suppl, , p. 9009 (DOI10.1200/jco.2014.32.15_suppl.9009, lire en ligne)
Wood AC, Krytska K, Ryles H, Sano R, Li N, King F, Smith T, Tuntland T, Kim S, Caponigro G, He YQ, « Abstract 1000: Combination CDK4/6 and ALK inhibition demonstrates on-target synergy against neuroblastoma », Cancer Research, vol. 74, no 19 Supplement, , p. 1000 (DOI10.1158/1538-7445.AM2014-1000)
